<?xml version="1.0" encoding="UTF-8"?>
<p id="Par23">Bayon et al. (
 <xref ref-type="bibr" rid="CR23">2018</xref>) developed vaccine formulations comprising nanostructured lipid carriers (NLC) grafted with p24 antigen, together with cationic NLC optimized for the delivery of immunostimulant CpG, which was able notably enhance immune responses against p24 manifested in specific antibody production and T cell activation in mice as well as in nonhuman primates.
</p>
